A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)
Year: 2010
Type: conference-abstract
Study design: Clinical Trial
Source: Blood
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: RG7112, MDM2 inhibitors, p53 activation, relapsed/refractory leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, oral small-molecule therapy
Open Access status: closed
OpenAlex ID: W2570629397
